DBV Technologies
DBVT • NASDAQ
DBV Technologies is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Daniel Tassé, with a market cap of $1.2B.
CEODaniel Tassé
Market Cap$1.2B
Biotechnology
Healthcare
Employees105.0
Websitedbvtechnologies.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for DBV Technologies
Date
Wednesday, April 29, 2026 (in 3 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.69
Revenue Estimate
$801.8K
Earnings History
Past 11 earnings reports for DBV Technologies
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Oct 28, 2025 | Q3 2025 | -$0.24Est: -$0.76 | +68.4% | $2.8MEst: $1.0M | +165.2% | — |
| Jul 29, 2025 | Q2 2025 | -$0.31Est: -$0.17 | -82.4% | $1.5MEst: $688.0K | +112.9% |  10-Q |
| Apr 30, 2025 | Q1 2025 | -$0.26 | — | $753.0K | — | 10-Q |
| Apr 11, 2025 | Q4 2024 | -$0.22Est: -$0.22 | 0.0% | $511.0KEst: $462.8K | +10.4% | 10-K/A |
| Nov 6, 2024 | Q3 2024 | -$1.60Est: -$1.75 | +8.6% | $1.1MEst: $1.4M | -22.3% | 10-Q |
| Jul 30, 2024 | Q2 2024 | -$1.70Est: -$2.25 | +24.4% | $1.2MEst: $1.7M | -30.9% | 10-Q |
| May 7, 2024 | Q1 2024 | -$1.40Est: -$2.10 | +33.3% | $1.4MEst: $2.3M | -38.3% | 10-Q |
| Mar 7, 2024 | Q4 2023 | -$0.60Est: -$2.50 | +76.0% | $8.9MEst: $1.2M | +658.5% | 10-K |
| Oct 31, 2023 | Q3 2023 | -$0.90Est: -$2.40 | +62.5% | $2.4MEst: $1.3M | +86.0% | — |
| Jul 31, 2023 | Q2 2023 | -$1.30Est: -$1.30 | 0.0% | $2.3MEst: $1.0M | +130.0% | 10-Q |
| May 4, 2023 | Q1 2023 | -$1.10Est: -$2.10 | +47.6% | $2.2MEst: $1.2M | +81.8% | — |